Form 4 for NRXP NRX Pharmaceuticals, Inc.
Accepted 2023-09-11 00:00:00 ET · period of report 2023-08-30 · accession 0001415889-23-013137 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-09-11 | 2023-08-30 | NRXP | Hurvitz Chaim | Dir | P - Purchase | $0.29 | +70.0K | 570.0K | +14% | +$20.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.001 per share | 2023-08-30 | P | A | 70,000 | $0.29 | 570,000 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected. |